© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 11, 937-939,
June 7, 2000
© 2000 Oxford University Press
BRIEF COMMUNICATION |
Tissue Microarray Assessment of Prostate Cancer Tumor Proliferation in African- American and White Men
Affiliations of authors: E. E. Perrone, N. R. Mucci (Department of Internal Medicine), C. Theoharis (Department of Pathology), S. Hayasaka, J. M. G. Taylor (Department of Biostatistics), K. A. Cooney (Department of Internal Medicine and Section of Urology, Department of Surgery), M. A. Rubin (Department of Pathology and Section of Urology, Department of Surgery), University of Michigan, Ann Arbor.
Correspondence to: Mark A. Rubin, M.D., Department of Pathology, University of Michigan, 1500 E. Medical Center Dr., Rm. 2G332/Box 0054, Ann Arbor, MI 48109-0054 (e-mail: marubin@umich.edu).
Prostate cancer is a major health-care problem for African-American men. The age-adjusted incidence of prostate carcinoma in African-American men is approximately 50% greater than in white men. Furthermore, studies (1–3) have consistently demonstrated that the mortality rate from prostate cancer is significantly greater in African-American men than in white men. This fact remains true, even after adjustment for stage at presentation (2). Some researchers have speculated that variable access to health care may substantively contribute to the disparate prostate cancer survival between racial groups. Robbins et al. (3) recently reported on survival from prostate carcinoma in participants in a large health-care maintenance organization in which one would assume that prostate carcinoma was detected and treated similarly in all races. In that study, the death rate from prostate cancer was higher in African-American men than in white men after adjustment for age and
NOTES
REFERENCES
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S.-M. Sheen-Chen, C.-C. Huang, R.-P. Tang, F.-F. Chou, and H.-L. Eng Prognostic Value of Signal Transducers and Activators of Transcription 3 in Breast Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2286 - 2290. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Santagata, F. Demichelis, A. Riva, S. Varambally, M. D. Hofer, J. L. Kutok, R. Kim, J. Tang, J. E. Montie, A. M. Chinnaiyan, et al. JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence Cancer Res., October 1, 2004; 64(19): 6854 - 6857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rubin, S. Varambally, R. Beroukhim, S. A. Tomlins, D. R. Rhodes, P. L. Paris, M. D. Hofer, M. Storz-Schweizer, R. Kuefer, J. A. Fletcher, et al. Overexpression, Amplification, and Androgen Regulation of TPD52 in Prostate Cancer Cancer Res., June 1, 2004; 64(11): 3814 - 3822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Kleer, Q. Cao, S. Varambally, R. Shen, I. Ota, S. A. Tomlins, D. Ghosh, R. G. A. B. Sewalt, A. P. Otte, D. F. Hayes, et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells PNAS, September 30, 2003; 100(20): 11606 - 11611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Vrolijk, W. Sloos, W. Mesker, P. Franken, R. Fodde, H. Morreau, and H. Tanke Automated Acquisition of Stained Tissue Microarrays for High-Throughput Evaluation of Molecular Targets J. Mol. Diagn., August 1, 2003; 5(3): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Fu, P. C. Smith, L. Zhang, M. A. Rubin, R. L. Dunn, Z. Yao, and E. T. Keller Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis J Natl Cancer Inst, June 18, 2003; 95(12): 878 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Xin, D. R. Rhodes, C. Ingold, A. M. Chinnaiyan, and M. A. Rubin Dysregulation of the Annexin Family Protein Family Is Associated with Prostate Cancer Progression Am. J. Pathol., January 1, 2003; 162(1): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rubin, M. Zhou, S. M. Dhanasekaran, S. Varambally, T. R. Barrette, M. G. Sanda, K. J. Pienta, D. Ghosh, and A. M. Chinnaiyan {alpha}-Methylacyl Coenzyme A Racemase as a Tissue Biomarker for Prostate Cancer JAMA, April 3, 2002; 287(13): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Gancberg, A Di Leo, G Rouas, T Jarvinen, A Verhest, J Isola, M J Piccart, and D Larsimont Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma J. Clin. Pathol., April 1, 2002; 55(4): 315 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Manley, N. R. Mucci, A. M. De Marzo, and M. A. Rubin Relational Database Structure to Manage High-Density Tissue Microarray Data and Images for Pathology Studies Focusing on Clinical Outcome : The Prostate Specialized Program of Research Excellence Model Am. J. Pathol., September 1, 2001; 159(3): 837 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O.-P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum. Mol. Genet., April 1, 2001; 10(7): 657 - 662. [Abstract] [Full Text] [PDF]
|
|